UNVC - Univec - 500 Beiträge pro Seite

[dirkbe]

Great news for this manufacturer of single use syringes.
Only trading at $0.53. 52 week high $1.34

Here`s the news...

Thursday August 17, 9:30 am Eastern Time
Press Release
UNIVEC and Terumo Sign Licensing Agreement for Production of Auto-Disable Syringes
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 17, 2000--The Farmingdale-based UNIVEC Corporation (NASDAQ:UNVC - news), the internationally recognized maker of auto-disable syringes, has entered into a long term licensing agreement with Terumo Europe N.V. (Belgium) for UNIVEC`s proprietary auto-destruct syringe technology. The agreement will enable Terumo to produce auto-destruct syringes that are required by the World Health Organization and its collaborating partners for mass immunization campaigns.

Terumo enters into a licensing agreement with UNIVEC along with purchasing its specially designed equipment to assemble the auto destruct syringes. Other terms of the agreement were not disclosed.

``We are pleased to be in this relationship with one of the world`s leading syringe manufacturers and its management team whose members are so committed to their growing market,`` said Joel Schoenfeld, Chairman of UNIVEC.

``UNIVEC`s technology is at the forefront of the industry and we look forward to working closely with Terumo on this project,`` said Dr. Alan Gold, CEO of UNIVEC.

The UNIVEC technology is for auto-disable syringes that can effectively deliver vaccines in a safer manner than with traditional syringes. The UNIVEC syringe prevents re-use and the needless spread of disease. The devices can deliver predetermined doses from 0.05 to 1cc needed to deliver medication, which may prevent contagious diseases from spreading.

Terumo manufactures and sells a broad range of medical products that contribute to society through healthcare by responding to the needs of health care providers and the people they serve. Terumo began to produce disposable syringes in 1963 - the first produced in Japan - specifically designed for safety.

The management of Terumo knows how important safe medical devices are and how essential it is for present day medicine to avert infections via instruments and to promote the security of both hospital workers and patients.

UNIVEC is world leader in auto-disable syringes and is leading the global move for a conversion to AD-Sy from multi-use syringes which are acknowledged by the World Health Organization to be responsible for the spread of disease to millions of people each year.

Terumo Europe NV is a division of Terumo Corporation - Japan, a global medical technology company that develops, manufactures and markets a broad range of products and services. For the fiscal year ended March 31st, 2000, Terumo Corporation reported total revenue of 171 Billion Yen.

``This is a major step in the direction needed to be taken by the health care industry worldwide. I applaud Terumo for this courageous move and I know it will mean other suppliers worldwide will follow suit,`` said Schoenfeld.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company`s Securities and Exchange filings under ``Risk Factors,`` including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company`s proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks.)


--------------------------------------------------------------------------------
Contact:

UNIVEC
Joel Schoenfeld, 631/777-2000
[e-mail]

[dirkbe]

Summary of the interview on http://www.ceocast.com !

I must say I feel good after listening. For two reasons.

1. This company is going to improve the lives of millions of people throughout the world

2. The future of the company`s looks very good.

As I understand this agreement with Terumo is non exclusive. This means Univec can close similar deals with other companies. And guess what... in this case Univec isn`t negociating with companies but with governments!!

They are in talks with India and China. That means almost 2 billion people or 1/3 of the entire world population!!

The talks are not about sales but about production. Univec will deliver the necessary equipment so the domestic population can produce its own syringes. Of course this is on a royalty basis, similar to the Terumo deal.

Some more highlights of the interview:

1. Terumo is the Becton Dickinson of Asia
2. The agreement is a 12 year agreement
3. Terumo will buy equipment from Univec to produce the syringes.


To conclude:

Despite its low and unfair share price this company simply deserves our patience. I don`t know how long it will take before the investment community will discover the potential of Univec but eventually it will get there where it belongs, where it came from: Nasdaq

It will rewards us all both people across the world and shareholders (in that order)...


Dirk

[dirkbe]

News today.

UNIVEC Praises Signing of AIDS Bill; Attacks Re-Usable Syringes for Spreading Infection Adding to the Epidemic
Tuesday, August 22, 2000 10:34 AM


FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 22, 2000--The Farmingdale-based UNIVEC
Corporation (UNVC/NASDAQ), the internationally recognized maker of auto-disable syringes, today praised President Clinton for signing over the weekend the "Global AIDS and Tuberculosis Relief Act of
2000."

The legislation represents the latest U.S. effort in the long-term global fight against HIV/AIDS and its related threat of tuberculosis. This new initiative builds on the $1.4-billion already invested by the United States in international AIDS programs since the start of the epidemic.

"Last year, AIDS killed 2.8 million people world-wide," said Joel Schoenfeld, chairman of UNIVEC. "I praise our benevolence and compassion but criticize our complacency in adding to the epidemic
proportions by not outlawing re-usable syringes, which every humanitarian agency acknowledges increases the risks of infection."

"We pour millions more into vaccination programs with re-usable syringes that could be improperly sterilized and later discarded to be used multi-times in the drug culture," said Schoenfeld. "It is,
seemingly, obvious that we are also paying to spread infection, unless we also mandate universally auto-disable syringes."

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a
number of factors, including those set forth in the company`s Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company`s proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks).


CONTACT: UNIVEC Corporation, Farmingdale
Joel Schoenfeld, 631/777-2000
[e-mail]

[dirkbe]

Annual shareholder meeting on August 25.
Expect to hear details about the recent deal with Terumo and contacts with the Indian and Chinese government

Dirk

[dirkbe]

Great news. Univec now has a new IR company which will give UNVC more exposure to the investor community!
August 25, 2000 09:46

UNIVEC, Inc. Retains Investor Relations Firm
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Aug. 25, 2000--The Farmingdale-based UNIVEC Corporation (UNVC/NASDAQ), and internationally recognized maker of auto-disable syringes, announced today the selection of CEOcast, Inc. as its new investor relations firm. The selection was announced today by its Chairman, Joel Schoenfeld.
CEOcast`s investor relations services will include daily contact with retail and institutional investors and the brokerage community, dissemination of information to Univec`s investor base, presentation to the Wall Street Community and management of internet communications.

Mr. Schoenfeld stated, "We selected CEOcast from many candidates because we believe that they are an ideal partner to assist us in raising our profile within the investment community. We believe that our unique range of affordable quality products is designed to ensure the safest and most effective treatment available for healthcare workers and patients alike.

Mr. Schoenfeld is currently featured in an interview discussing the Company`s recent Licensing of technology to Terumo Europe N.V. (Belgium) in an interview at CEOcast.com. "We are very impressed with the international need for the safety syringe," said Ken Sgro, CEOcast President. "We believe that the company will not only make profits, but will make a difference in human life."

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the company`s Securities and Exchange filings under "Risk Factors," including risks relating to dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the company`s proposed products (such as marketing, safety, regulatory, patent product liability, supply, competition and other risks).


CONTACT: UNIVEC Corporation, Farmingdale
Joel Schoenfeld, 631/777-2000
[e-mail]

[dirkbe]

Did some digging on the website of ceocast, the new IR company of Univec: impressive, read...

CEOcast is the premier source of original and syndicated streaming broadcast interviews of Chief Executive Officers at public and private news-making companies. Organized by industry, its analysts average over 15 years experience covering and evaluating Wall Street`s leading companies

CEOcast`s programming is distributed to millions of on-line investors at over 700 financial web sites as well as to more than 20,000 portfolio managers, buy-side analysts and traders at more than 3,300 North American institutions. Content is also disseminated to over 7,000 investment research professionals representing over 425 institutions. All content is copyrighted to protect our licensing partners.

http://www.ceocast.com/aboutus.cfm

I am sure the investment world will notice Univec and its potential real soon...

Dirk

Remember UNVC now trading at $0.55, 52 week high is $1 3/8

[dirkbe]

Looking good
100K traded and price up: 0.56 - 0.68

Shareholder Meeting must have been a success. They`ve probably heard the Terumo story and an update on the talks with the Indian and Chinese government.

I am curious what the IR company "CEOCast" will do for the company. 20,000 analysts and 500,000 members among their contacts is an awful lot.

Let`s see what the future brings. I feel confident.

DDD

[dirkbe]

This week Univec shares were traded actively. I strongly believe the comapny is being discovered by a lot of new investors thanks to CEOCast.

Date Last Volume Open Day`s range
Fri Sep 01 0.66 141,100 0.66 0.56 - 0.75
Thu Aug 31 0.66 71,100 0.63 0.56 - 0.66
Wed Aug 30 0.59 146,100 0.56 0.52 - 0.61
Tue Aug 29 0.56 126,000 0.56 0.53 - 0.65


DDD

[dirkbe]

More interesting volume numbers

The amount of traded shares almost doubled in August 2000, compared to July.

August: 945,370 shares
July 576,289 shares
June: 473,205
May: 213,563
April: 198,255
March: 1,411,292 (month when the annual report was released)
February: 357,121
January: 392,630

http://www.otcbb.com/asp/tradeact_mv.asp?Month=8-1-2000&sear…
e=UNVC&downloadname=mv200008.exe&view.x=35&view.y=6


Looking forward to September. (Sep 1: 141,000 shares traded)

DDD

[dirkbe]

All small bits help.

Equity Alert (http://www.equityalert.com) has made news alerts for UNVC available to its members.
Univec told me they did that "unsollicited" and they were very happy about it.
Univec is now looking how they can profit even more from Equity Alert`s services.

This is again a way of getting more exposure for Univec.
To me it`s clear they are preparing themselves for some major accomplisments.
Suppose some very good news would come along and no one would hear it or could read it,
wouldn`t that be a shame...

Dirk